Consorzio Mario Negri Sud, Via Nazionale, Santa Maria Imbaro, Italy.
Curr Atheroscler Rep. 2009 Nov;11(6):440-7. doi: 10.1007/s11883-009-0066-y.
During the past three decades, the protective role of omega (n)-3 polyunsaturated fatty acids (PUFA), mainly eicosapentaenoic acid and docosahexaenoic acid, in patients with coronary heart disease has been widely reported. The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure (GISSI-HF) study, a large-scale clinical trial, recently showed that n-3 PUFA (850-882 mg/d) reduced mortality and admission to the hospital for cardiovascular reasons in patients with chronic heart failure (HF) who were already receiving recommended therapies. The favorable effects of n-3 PUFA in GISSI-HF suggest that marine fish oils could confer protection in HF mainly through their antiarrhythmic action and in part by influencing the mechanisms related to HF progression. This article reviews recent clinical and experimental evidence on the effect of n-3 PUFA in coronary heart disease, with particular attention on HF and its pathophysiologic mechanisms.
在过去的三十年中，ω(n)-3 多不饱和脂肪酸（PUFA），主要是二十碳五烯酸和二十二碳六烯酸，在冠心病患者中的保护作用已被广泛报道。意大利心肌梗死存活研究组-心力衰竭（GISSI-HF）的一项大型临床试验最近表明，n-3 PUFA（850-882mg/d）可降低已接受推荐治疗的慢性心力衰竭（HF）患者的死亡率和因心血管原因住院的次数。GISSI-HF 中 n-3 PUFA 的有利作用表明，海洋鱼油主要通过其抗心律失常作用，部分通过影响与 HF 进展相关的机制，在 HF 中可能具有保护作用。本文综述了 n-3 PUFA 在冠心病中的临床和实验证据，特别关注 HF 及其病理生理机制。
